Developer docs
API playgroundTry for free, no card

Search company profiles

Allucent

Full company profile

uuid0005gwh

Namestring
Allucent
Legal namestring
Allucent
Websiteurl
allucent.com
Company typeenum
Private
Founded yearint
1993
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersCary, United States
HQ citystring
Cary
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices27 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical research services, drug development consulting, regulatory strategy services, clinical pharmacology modeling, pharmacovigilance services
Industry8 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Other Scientific and Technical Consulting Services541690
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Organization (CRO) Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1CRO Clinical Development Services
TypeProfessional Services
Description

Allucent generates revenue as a full-service CRO providing comprehensive clinical development services to small and mid-sized biopharma companies. Revenue is derived from service contracts spanning study design, clinical operations, data management, biostatistics, regulatory strategy, pharmacovigilance, and post-marketing surveillance across all trial phases. The model is project-based and service-contract driven, with engagements ranging from standalone functional support to full-service integrated CRO partnerships. The company has supported 105+ successful marketing applications and 50+ approved and marketed products.

allucent.com
2Regulatory Strategy & Submissions
TypeProfessional Services
Description

Regulatory strategy consulting and submissions services, including IND/NDA/BLA preparation, eCTD publishing, CMC and preclinical regulatory support, and GxP consulting. Revenue is generated through project-based consulting engagements and regulatory submission service contracts, supported by a team of 12 former regulators from 6 regulatory agencies.

allucent.com
3Clinical Pharmacology & Modeling Services
TypeProfessional Services
Description

Specialized clinical pharmacology services including pharmacokinetics, pharmacodynamics, modeling and simulation, translational DMPK, and embedded clinical pharmacologist consulting. Supports 650+ drugs across all modalities, routes of administration, and therapeutic areas, with 6,650+ PK/PD/TK/QTc translational analyses conducted. Revenue from project-based and retainer consulting engagements.

allucent.com
4Drug Safety & Pharmacovigilance Services
TypeProfessional Services
Description

Post-marketing and clinical trial drug safety and pharmacovigilance services including PV system setup, aggregate safety reports, risk management, global QPPV services, and expedited adverse event reporting. Revenue from ongoing service contracts with biopharma sponsors across clinical and post-marketing lifecycle stages.

allucent.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Full-service CRO engagement model covering all clinical development phases
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is negotiated on a project-by-project basis. Engagements range from full-service integrated CRO partnerships to standalone functional support in areas such as biostatistics, data management, regulatory strategy, clinical pharmacology, and pharmacovigilance. No public pricing is available.

allucent.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1IGNITE Site Network
Description

Allucent's Integrated Global Network for Innovative Trial Execution (IGNITE™) is a global network of prequalified clinical research sites therapeutically aligned to the Allucent Centers of Expertise (ACE), designed to increase study predictability including study start-up, patient enrollment and overall study execution.

allucent.com
Core offering1 text field

Allucent is a full-service Contract Research Organization (CRO) providing integrated clinical development services to small and mid-sized biopharma companies. The company offers end-to-end capabilities across clinical trial operations, clinical pharmacology and modeling & simulation, regulatory strategy and submissions, drug safety and pharmacovigilance, clinical data management, biostatistics, and medical monitoring, delivered through a proprietary IGNITE site network of 193 prequalified sites across 12 countries. Engagements span from preclinical through post-marketing surveillance under flexible full-service or standalone functional outsourcing models.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 105+ successful marketing applications supported
+4 more records
Product overview1 text field

Allucent is a global, full-service Contract Research Organization (CRO) offering an integrated platform of clinical development services for small and mid-sized biopharma companies. The portfolio centers on five core service pillars: Clinical Development Services (encompassing study start-up, patient recruitment, decentralized trials, data management, biostatistics, and medical monitoring), Clinical Pharmacology (including pharmacokinetics, modeling & simulation, and translational DMPK), Regulatory Strategy (spanning submissions, GxP consulting, and clinical/CMC strategy), Drug Safety & Pharmacovigilance (covering clinical trial safety and post-marketing surveillance), and the IGNITE Site Network (a global network of 193+ prequalified research sites). Supporting these core services are specialized modules including Patient Direct Trials (decentralized trial technology), Clinical Data Management, Biostatistics & Statistical Programming, Medical Monitoring, Patient Recruitment & Retention, Regulatory Submissions (using LORENZ docuBridge), Biostatistical Consulting, and Embedded Clinical Pharmacologist services. The platform is delivered through Allucent's Centers of Expertise (ACEs) structure focused on oncology, neuroscience, cardiometabolic, immunology, rare diseases, and advanced therapies.

Product and service7 records
1Clinical Development Services
CategoryClinical Research Services
Description

Comprehensive clinical trial operations including study start-up, patient recruitment, decentralized trials, data management, biostatistics, and medical monitoring for early- and late-phase programs. Designed for small and mid-sized biotech and biopharma sponsors needing end-to-end operational support.

2Clinical Pharmacology Services
CategoryClinical Pharmacology Services
Description

Drug development insights through pharmacokinetics, pharmacodynamics, modeling and simulation, translational DMPK, and clinical pharmacology study design including First-in-Human, SAD/MAD, and bioequivalence studies. Supports 650+ drugs across all modalities, routes of administration, and therapeutic areas.

3Regulatory Strategy Services
CategoryRegulatory Consulting Services
Description

Regulatory and drug development consulting including submissions strategy, compliance planning, expedited pathway designations, orphan drug strategy, pediatric development plans, eCTD publishing, GxP consulting, CMC and preclinical support, and biostatistical consulting. Supports IND, NDA, BLA, IDE, and IMPD submissions to FDA, EMA, Health Canada, and MHRA.

4Drug Safety & Pharmacovigilance Services
CategoryPharmacovigilance Services
Description

Patient safety solutions spanning clinical trial safety, post-marketing surveillance, risk management, global QPPV services, and PV system setup and maintenance for biopharma sponsors across clinical and post-marketing lifecycle stages.

5IGNITE Site Network
CategoryClinical Site Network
Description

Global network of prequalified clinical research sites with 193 sites across 12 countries and a 40M+ patient pool. Therapeutically aligned to Allucent Centers of Expertise (ACEs) to accelerate study start-up, improve enrollment predictability, and deliver consistent trial execution from first patient in (FPI) through last patient in (LPI).

6Government & Public Health Services
CategoryGovernment Clinical Research Services
Description

CRO services tailored for government-sponsored clinical research with partners including BARDA, U.S. Department of Defense, NINDS, and NIAID. Brings collective expertise to navigate unique regulatory and compliance requirements of public health programs, including FDA Animal Rule applications.

7Patient Direct Trials (Decentralized Clinical Trials)
CategoryDecentralized Clinical Trial Services
Description

Decentralized clinical trial solution featuring eCOA, telehealth, site data capture, sensors & wearables, eConsent, patient notifications, home health, and IMP delivery, with real-time data visualization for sites. Designed for hybrid and fully decentralized study designs.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1Xtalks
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-05-28
Description

Xtalks hosts educational webinars featuring Allucent experts on clinical development topics including participant-site readiness for rare disease trials, AI and emerging technologies in clinical trials, pediatric rare disease trials, and navigating the Animal Rule. Xtalks serves as official Media Partner for the Toronto Life Sciences and Biotech Summit where Allucent presents.

prnewswire.com
2Xtalks
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-04-20
Description

Xtalks partnered with Allucent for a webinar on AI and emerging technologies in clinical trials, part of Xtalks' role as official Media Partner for the Toronto Life Sciences and Biotech Summit. Allucent experts discuss practical AI applications across protocol development, patient recruitment, trial operations, and regulatory considerations for decentralized trial models.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

Allucent maintains specialized capabilities for government-sponsored and public health research, partnering with leading agencies including BARDA, Department of Defense, NINDS, and NIAID. The government services A-Team brings collective expertise to navigate unique regulatory and compliance requirements of government-sponsored clinical research programs.

4NINDS (National Institute of Neurological Disorders and Stroke)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

Allucent partners with NINDS for government-sponsored clinical research programs in neuroscience, navigating the unique regulatory and compliance requirements of NIH-sponsored drug development.

prnewswire.com
5NIAID (National Institute of Allergy and Infectious Diseases)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

Allucent partners with NIAID for government-sponsored clinical research programs in infectious diseases and vaccines, leveraging the institute's public health research mandate and Allucent's operational execution capabilities.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

Allucent partners with the U.S. Department of Defense for government-sponsored clinical research, navigating unique regulatory and compliance requirements for defense-related public health programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-30
Description

Allucent serves as the contract research organization managing the Phase 2 clinical trial for Lucid-MS, Quantum BioPharma's first-in-class neuroprotective drug candidate for multiple sclerosis. Allucent manages site selection, patient recruitment, and data analysis for the study. The trial was expected to begin in Q2 2026 pending regulatory approvals. A binding Letter of Intent was signed in March 2026.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-30
Description

Massachusetts General Hospital scientists collaborate with Allucent on Phase 2 trials and validation of a novel PET imaging tracer for monitoring myelin integrity in the Lucid-MS multiple sclerosis program for Quantum BioPharma. The collaboration supports development of a PET imaging technique capable of directly measuring myelin integrity, addressing a critical challenge in remyelinating therapies.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-29
Description

Queens University Belfast collaborated with Allucent on a webinar focused on transforming pediatric rare disease trials through model-informed drug development and specialized site networks. The partnership featured experts from both organizations discussing population pharmacokinetic modeling and clinical trial simulation approaches.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-17
Description

Allucent was selected to support the preparation and planned submission of an Investigational New Drug application to the FDA for SPC-15, an intranasal prophylactic treatment for PTSD. Services include GLP toxicology and drug-device study data coordination, with Phase 1 clinical trials planned following FDA IND approval. A non-binding Letter of Intent was established.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Medpace is a mid-to-large clinical CRO focused on small and mid-sized biopharma sponsors — directly comparable to Allucent's go-to-market model. Both compete on therapeutic depth and a high-touch, full-service operating model rather than scale-only differentiation, making Medpace the closest publicly traded comp.

TypeDirect peer
Description

Worldwide Clinical Trials is a privately held, mid-sized full-service CRO with a strong focus on small and mid-sized biopharma sponsors across complex therapeutic areas. Its specialty positioning, mid-size scale, and biotech-centric GTM closely mirror Allucent's profile.

TypeEmerging player
Description

Rho is a privately held, mid-sized CRO with strong focus on small and mid-sized biopharma sponsors, particularly in rare disease and immunology. It is a smaller, more focused peer with comparable biotech sponsor specialization.

TypeBroad incumbent
Description

Charles River provides preclinical and clinical services with strong biotech sponsor coverage in early-phase and discovery work. Its preclinical-clinical integration and biotech focus make it a partial competitor in the same sponsor segment.

TypeBroad incumbent
Description

Parexel is a large global CRO with strong biotech and small/mid-sponsor focus, particularly in oncology and rare disease. Its biotech-focused operating model and global site footprint compete with Allucent for the same sponsor segment.

TypeBroad incumbent
Description

IQVIA is the largest global CRO with broad biotech, pharma, and post-approval service capabilities. It is a competitive incumbent across Allucent's therapeutic areas but operates at materially larger scale with broader portfolio breadth.

TypeBroad incumbent
Description

Syneos Health is a large CRO with combined clinical and commercial services, serving biotech and pharma sponsors across all trial phases. It competes with Allucent in clinical development and increasingly in decentralized trial delivery.

TypeBroad incumbent
Description

ICON is a top-3 global CRO with full-service clinical development and significant biotech sponsor coverage. Following its PRA Health Sciences acquisition, ICON has expanded its biotech and specialty franchise and competes broadly with Allucent in clinical operations.

TypeDirect peer
Description

Premier Research is a specialty CRO focused on small and mid-sized biopharma and rare disease/oncology programs. Its therapeutic specialization, mid-size footprint, and biotech sponsor focus make it a closely comparable niche CRO peer.

TypeBroad incumbent
Description

Labcorp Drug Development is a top global CRO with integrated central laboratory and clinical development services. It competes broadly across Allucent's therapeutic areas and offers end-to-end biotech sponsor programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses2 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles28 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Allucent

Contract Research Organization (CRO) Servicesallucent.com

Allucent firmographics

Firmographics
Name
Allucent
Legal name
Allucent
Website
https://allucent.com
Company type
Private
Founded year
1993
Operating status
Operating
Headcount range
1,001–5,000 employees
Ownership category
akta.pro rank

Allucent industry classification

Industry
Product category
Contract Research Organization (CRO) Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (541690)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)

Keywords

  • Clinical research services
  • Drug development consulting
  • Regulatory strategy services
  • Clinical pharmacology modeling
  • Pharmacovigilance services

Where Allucent is headquartered

Location

Headquarters

HQ city
Cary
HQ country
United States
HQ region
North America

Offices27 records

Markets served

Allucent business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. CRO Clinical Development Services: Allucent generates revenue as a full-service CRO providing comprehensive clinical development services to small and mid-sized biopharma companies. Revenue is derived from service contracts spanning study design, clinical operations, data management, biostatistics, regulatory strategy, pharmacovigilance, and post-marketing surveillance across all trial phases. The model is project-based and service-contract driven, with engagements ranging from standalone functional support to full-service integrated CRO partnerships. The company has supported 105+ successful marketing applications and 50+ approved and marketed products.
  2. Regulatory Strategy & Submissions: Regulatory strategy consulting and submissions services, including IND/NDA/BLA preparation, eCTD publishing, CMC and preclinical regulatory support, and GxP consulting. Revenue is generated through project-based consulting engagements and regulatory submission service contracts, supported by a team of 12 former regulators from 6 regulatory agencies.
  3. Clinical Pharmacology & Modeling Services: Specialized clinical pharmacology services including pharmacokinetics, pharmacodynamics, modeling and simulation, translational DMPK, and embedded clinical pharmacologist consulting. Supports 650+ drugs across all modalities, routes of administration, and therapeutic areas, with 6,650+ PK/PD/TK/QTc translational analyses conducted. Revenue from project-based and retainer consulting engagements.
  4. Drug Safety & Pharmacovigilance Services: Post-marketing and clinical trial drug safety and pharmacovigilance services including PV system setup, aggregate safety reports, risk management, global QPPV services, and expedited adverse event reporting. Revenue from ongoing service contracts with biopharma sponsors across clinical and post-marketing lifecycle stages.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractFull-service CRO engagement model covering all clinical development phases

Go-to-market motion1 record

Distribution channels1 record

Marketing channels9 records

Allucent product offering

Product offering

Core offering

Allucent is a full-service Contract Research Organization (CRO) providing integrated clinical development services to small and mid-sized biopharma companies. The company offers end-to-end capabilities across clinical trial operations, clinical pharmacology and modeling & simulation, regulatory strategy and submissions, drug safety and pharmacovigilance, clinical data management, biostatistics, and medical monitoring, delivered through a proprietary IGNITE site network of 193 prequalified sites across 12 countries. Engagements span from preclinical through post-marketing surveillance under flexible full-service or standalone functional outsourcing models.

Product overview

Allucent is a global, full-service Contract Research Organization (CRO) offering an integrated platform of clinical development services for small and mid-sized biopharma companies. The portfolio centers on five core service pillars: Clinical Development Services (encompassing study start-up, patient recruitment, decentralized trials, data management, biostatistics, and medical monitoring), Clinical Pharmacology (including pharmacokinetics, modeling & simulation, and translational DMPK), Regulatory Strategy (spanning submissions, GxP consulting, and clinical/CMC strategy), Drug Safety & Pharmacovigilance (covering clinical trial safety and post-marketing surveillance), and the IGNITE Site Network (a global network of 193+ prequalified research sites). Supporting these core services are specialized modules including Patient Direct Trials (decentralized trial technology), Clinical Data Management, Biostatistics & Statistical Programming, Medical Monitoring, Patient Recruitment & Retention, Regulatory Submissions (using LORENZ docuBridge), Biostatistical Consulting, and Embedded Clinical Pharmacologist services. The platform is delivered through Allucent's Centers of Expertise (ACEs) structure focused on oncology, neuroscience, cardiometabolic, immunology, rare diseases, and advanced therapies.

Differentiator

Problem solved

Functional benefit

Brands

  • IGNITE Site Network: Allucent's Integrated Global Network for Innovative Trial Execution (IGNITE™) is a global network of prequalified clinical research sites therapeutically aligned to the Allucent Centers of Expertise (ACE), designed to increase study predictability including study start-up, patient enrollment and overall study execution.

Products and services

  • Clinical Development Services Comprehensive clinical trial operations including study start-up, patient recruitment, decentralized trials, data management, biostatistics, and medical monitoring for early- and late-phase programs. Designed for small and mid-sized biotech and biopharma sponsors needing end-to-end operational support.
  • Clinical Pharmacology Services Drug development insights through pharmacokinetics, pharmacodynamics, modeling and simulation, translational DMPK, and clinical pharmacology study design including First-in-Human, SAD/MAD, and bioequivalence studies. Supports 650+ drugs across all modalities, routes of administration, and therapeutic areas.
  • Regulatory Strategy Services Regulatory and drug development consulting including submissions strategy, compliance planning, expedited pathway designations, orphan drug strategy, pediatric development plans, eCTD publishing, GxP consulting, CMC and preclinical support, and biostatistical consulting. Supports IND, NDA, BLA, IDE, and IMPD submissions to FDA, EMA, Health Canada, and MHRA.
  • Drug Safety & Pharmacovigilance Services Patient safety solutions spanning clinical trial safety, post-marketing surveillance, risk management, global QPPV services, and PV system setup and maintenance for biopharma sponsors across clinical and post-marketing lifecycle stages.
  • IGNITE Site Network Global network of prequalified clinical research sites with 193 sites across 12 countries and a 40M+ patient pool. Therapeutically aligned to Allucent Centers of Expertise (ACEs) to accelerate study start-up, improve enrollment predictability, and deliver consistent trial execution from first patient in (FPI) through last patient in (LPI).
  • Government & Public Health Services CRO services tailored for government-sponsored clinical research with partners including BARDA, U.S. Department of Defense, NINDS, and NIAID. Brings collective expertise to navigate unique regulatory and compliance requirements of public health programs, including FDA Animal Rule applications.
  • Patient Direct Trials (Decentralized Clinical Trials) Decentralized clinical trial solution featuring eCOA, telehealth, site data capture, sensors & wearables, eConsent, patient notifications, home health, and IMP delivery, with real-time data visualization for sites. Designed for hybrid and fully decentralized study designs.

Quantifiable outcome

  • 105+ successful marketing applications supported
  • +4 more outcomes

Companies that use Allucent

Customer profile

Named customers4 records

Segments1 record

Ideal customer profiles2 records

Allucent technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Allucent partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered minor and core.

  • XtalksminorGTM or Marketing Partner · 28 May 2026Xtalks hosts educational webinars featuring Allucent experts on clinical development topics including participant-site readiness for rare disease trials, AI and emerging technologies in clinical trials, pediatric rare disease trials, and navigating the Animal Rule. Xtalks serves as official Media Partner for the Toronto Life Sciences and Biotech Summit where Allucent presents.
  • XtalksminorGTM or Marketing Partner · 20 April 2026Xtalks partnered with Allucent for a webinar on AI and emerging technologies in clinical trials, part of Xtalks' role as official Media Partner for the Toronto Life Sciences and Biotech Summit. Allucent experts discuss practical AI applications across protocol development, patient recruitment, trial operations, and regulatory considerations for decentralized trial models.
  • BARDA (Biomedical Advanced Research and Development Authority)coreStrategic or Co-development Partner · 7 April 2026Allucent maintains specialized capabilities for government-sponsored and public health research, partnering with leading agencies including BARDA, Department of Defense, NINDS, and NIAID. The government services A-Team brings collective expertise to navigate unique regulatory and compliance requirements of government-sponsored clinical research programs.
  • NINDS (National Institute of Neurological Disorders and Stroke)coreStrategic or Co-development Partner · 7 April 2026Allucent partners with NINDS for government-sponsored clinical research programs in neuroscience, navigating the unique regulatory and compliance requirements of NIH-sponsored drug development.
  • NIAID (National Institute of Allergy and Infectious Diseases)coreStrategic or Co-development Partner · 7 April 2026Allucent partners with NIAID for government-sponsored clinical research programs in infectious diseases and vaccines, leveraging the institute's public health research mandate and Allucent's operational execution capabilities.
  • U.S. Department of DefensecoreStrategic or Co-development Partner · 7 April 2026Allucent partners with the U.S. Department of Defense for government-sponsored clinical research, navigating unique regulatory and compliance requirements for defense-related public health programs.
  • Quantum BioPharma Ltd.coreStrategic or Co-development Partner · 30 March 2026Allucent serves as the contract research organization managing the Phase 2 clinical trial for Lucid-MS, Quantum BioPharma's first-in-class neuroprotective drug candidate for multiple sclerosis. Allucent manages site selection, patient recruitment, and data analysis for the study. The trial was expected to begin in Q2 2026 pending regulatory approvals. A binding Letter of Intent was signed in March 2026.
  • Massachusetts General HospitalcoreStrategic or Co-development Partner · 30 March 2026Massachusetts General Hospital scientists collaborate with Allucent on Phase 2 trials and validation of a novel PET imaging tracer for monitoring myelin integrity in the Lucid-MS multiple sclerosis program for Quantum BioPharma. The collaboration supports development of a PET imaging technique capable of directly measuring myelin integrity, addressing a critical challenge in remyelinating therapies.
  • Queens University BelfastminorStrategic or Co-development Partner · 29 January 2026Queens University Belfast collaborated with Allucent on a webinar focused on transforming pediatric rare disease trials through model-informed drug development and specialized site networks. The partnership featured experts from both organizations discussing population pharmacokinetic modeling and clinical trial simulation approaches.
  • Silo PharmacoreStrategic or Co-development Partner · 17 November 2025Allucent was selected to support the preparation and planned submission of an Investigational New Drug application to the FDA for SPC-15, an intranasal prophylactic treatment for PTSD. Services include GLP toxicology and drug-device study data coordination, with Phase 1 clinical trials planned following FDA IND approval. A non-binding Letter of Intent was established.

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Allucent competitors and assessment

Company assessment

Direct peers

  • Medpace: Medpace is a mid-to-large clinical CRO focused on small and mid-sized biopharma sponsors — directly comparable to Allucent's go-to-market model. Both compete on therapeutic depth and a high-touch, full-service operating model rather than scale-only differentiation, making Medpace the closest publicly traded comp.
  • Worldwide Clinical Trials: Worldwide Clinical Trials is a privately held, mid-sized full-service CRO with a strong focus on small and mid-sized biopharma sponsors across complex therapeutic areas. Its specialty positioning, mid-size scale, and biotech-centric GTM closely mirror Allucent's profile.
  • Premier Research: Premier Research is a specialty CRO focused on small and mid-sized biopharma and rare disease/oncology programs. Its therapeutic specialization, mid-size footprint, and biotech sponsor focus make it a closely comparable niche CRO peer.

Emerging players

  • Rho: Rho is a privately held, mid-sized CRO with strong focus on small and mid-sized biopharma sponsors, particularly in rare disease and immunology. It is a smaller, more focused peer with comparable biotech sponsor specialization.

Broad incumbents

  • Charles River Laboratories: Charles River provides preclinical and clinical services with strong biotech sponsor coverage in early-phase and discovery work. Its preclinical-clinical integration and biotech focus make it a partial competitor in the same sponsor segment.
  • Parexel International: Parexel is a large global CRO with strong biotech and small/mid-sponsor focus, particularly in oncology and rare disease. Its biotech-focused operating model and global site footprint compete with Allucent for the same sponsor segment.
  • IQVIA: IQVIA is the largest global CRO with broad biotech, pharma, and post-approval service capabilities. It is a competitive incumbent across Allucent's therapeutic areas but operates at materially larger scale with broader portfolio breadth.
  • Syneos Health: Syneos Health is a large CRO with combined clinical and commercial services, serving biotech and pharma sponsors across all trial phases. It competes with Allucent in clinical development and increasingly in decentralized trial delivery.
  • ICON plc: ICON is a top-3 global CRO with full-service clinical development and significant biotech sponsor coverage. Following its PRA Health Sciences acquisition, ICON has expanded its biotech and specialty franchise and competes broadly with Allucent in clinical operations.
  • Labcorp Drug Development (formerly Covance): Labcorp Drug Development is a top global CRO with integrated central laboratory and clinical development services. It competes broadly across Allucent's therapeutic areas and offers end-to-end biotech sponsor programs.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Allucent social profiles

Digital presence

Allucent compliance and trust

Trust signal

Compliance2 records

Allucent financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Allucent leadership team

Management profile

Number of profiles

Profiles28 records

Allucent funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Allucent M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Allucent

What does Allucent do?

Allucent is a full-service Contract Research Organization (CRO) providing integrated clinical development services to small and mid-sized biopharma companies. The company offers end-to-end capabilities across clinical trial operations, clinical pharmacology and modeling & simulation, regulatory strategy and submissions, drug safety and pharmacovigilance, clinical data management, biostatistics, and medical monitoring, delivered through a proprietary IGNITE site network of 193 prequalified sites across 12 countries. Engagements span from preclinical through post-marketing surveillance under flexible full-service or standalone functional outsourcing models.

Is Allucent a public or private company?

Allucent is a private company. It is classified as unknown and is currently operating.

When was Allucent founded?

Allucent was founded in 1993. It employs 1,001 to 5,000 people.

Where is Allucent based?

Allucent is headquartered in Cary, United States, in the North America region.

How does Allucent make money?

Four revenue lines are on record. CRO Clinical Development Services are the primary driver. The others are regulatory Strategy & Submissions, clinical Pharmacology & Modeling Services and drug Safety & Pharmacovigilance Services.

Who are Allucent's main competitors?

Direct peers on record are Medpace, Worldwide Clinical Trials and Premier Research. Rho is listed as an emerging player. Broad incumbents are Charles River Laboratories, Parexel International, IQVIA, Syneos Health, ICON plc and Labcorp Drug Development (formerly Covance).

Does Allucent have an API?

No public API is recorded for Allucent.

What industry is Allucent in?

Allucent's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PRESSBEEAllucent Appoints Chief Medical Officer and Infectious Disease Therapeutic Strategy Head ...Middle EastAllucent announced the appointments of Hubert Bland and Norman Waters to strengthen its expertise in life cycle drug development. The appointments are intended to enhance Allucent's specialized expertise and integrated support for biopharma companies.PR NewswireAllucent Appoints Chief Medical Officer and Infectious Disease Therapeutic Strategy HeadAllucent appointed Hubert Bland as Chief Medical Officer and Norman Waters as Therapeutic Strategy Head for Infectious Disease. Bland brings over 30 years in medical affairs and safety, while Waters, a retired Army colonel, leads infectious disease development. The appointments aim to support small and mid-sized biopharma clients in drug development.Clinical Trials ArenaAllucent unveils IGNITE network for clinical trialsAllucent has launched the Integrated Global Network for Innovative Trial Execution (IGNITE), a clinical trial network comprising over 250 pre-qualified research sites. The initiative aims to accelerate trial delivery by offering feasibility assessments within 72 hours and committing to site activation within 60 days in North America and three to four weeks internationally after regulatory approval.PR NewswireAllucent Launches IGNITE™ Site Network to Enhance Speed, Quality, and Predictability Across Clinical Trial DeliveryAllucent, a global specialty CRO for small and mid-sized biopharma, announced the launch of IGNITE (Integrated Global Network for Innovative Trial Execution), a performance-based network encompassing more than 250 pre-qualified clinical research sites. The network is built on long-term strategic site partnerships and provides defined execution commitments including 72-hour feasibility responses and site activation within 60 days of final protocol in North America. This launch strengthens Allucent's specialty CRO model by bringing together therapeutic expertise, technology and AI, site strategy, and global trial execution capabilities.MorningstarAllucent Launches IGNITE™ Site Network to Enhance Speed, Quality, and Predictability Across Clinical Trial DeliveryAllucent, a global specialty contract research organization serving small and mid-sized biopharma companies, announced the launch of IGNITE (Integrated Global Network for Innovative Trial Execution), a performance-based global network encompassing more than 250 pre-qualified clinical research sites. The network is built on long-term strategic site partnerships and includes defined execution commitments such as 72-hour feasibility responses, site activation within 60 days in North America, and access to patient populations representing more than 50 million individuals across six therapeutic areas. The launch further strengthens Allucent's specialty CRO model by integrating therapeutic expertise, site strategy, and global trial execution to help emerging biopharma navigate complex development programs.GlobeNewswireThe Quest to Repair What Multiple Sclerosis Takes AwayQuantum BioPharma Ltd. has filed an Investigational New Drug application with the U.S. FDA for Lucid-MS, a first-in-class drug candidate for multiple sclerosis that directly targets the myelin sheath rather than modulating the immune system like existing treatments. The company completed phase 1 clinical trials in healthy volunteers with a favorable safety profile and is preparing to initiate phase 2 efficacy trials through a partnership with contract research organization Allucent. Quantum BioPharma is also collaborating with Massachusetts General Hospital to validate a novel PET imaging technique capable of directly measuring myelin integrity, addressing a critical challenge in developing remyelinating therapies.Financial PostNovel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple SclerosisQuantum BioPharma Ltd. submitted its Investigational New Drug application to the U.S. FDA in April 2026 for Lucid-MS (Lucid-21-302), a first-in-class neuroprotective drug candidate that directly targets and has been shown in preclinical studies to prevent and reverse myelin degradation in multiple sclerosis, marking a potential advancement beyond existing immune-modulating therapies. The company completed Phase 1 human trials in 2023 demonstrating a favorable safety profile, and has partnered with contract research organization Allucent and Massachusetts General Hospital scientists to execute Phase 2 trials and validate a novel PET imaging tracer for monitoring myelin integrity.GlobeNewswireNovel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple SclerosisQuantum BioPharma is advancing Lucid-MS, a first-in-class drug targeting the myelin sheath in multiple sclerosis, into phase 2 clinical trials. The company submitted its IND application in April 2026, and a joint study with Massachusetts General Hospital is validating a PET tracer to monitor myelin integrity.PR NewswireStrengthen Participant-Site Readiness for Complex Rare Disease Trials, Upcoming Webinar Hosted by XtalksXtalks has announced a free webinar on June 18, 2026, focused on strengthening participant-site readiness for complex clinical trials, particularly in rare diseases. The webinar will feature speakers from uMotif, Allucent, Empatica, and Accellacare discussing topics including reducing participant burden, improving site engagement, and leveraging technology to streamline trial execution.FierceBiotechExecuting biomarker-driven oncology trialsBrant Nicks of Allucent discusses operational and regulatory challenges in biomarker-driven oncology trials, including high screen failure rates and assay validation. He notes extended safety follow-up and tumor board integration as key considerations, and mentions FDA's real-time data initiative. The conversation also covers balancing CAR-T access with long-term safety data.